Latest news and articles about license-out deals
Total: 1 articles found
AI is transforming drug discovery from an expensive exercise in trial-and-error into a data- and compute-driven engineering problem. The result is a pragmatic partnership between American algorithmic and compute strength and China’s unrivalled clinical scale, producing record licensing deals even as regulatory and scientific bottlenecks persist.